The TPD52L2 antibody targets the tumor protein D52-like 2 (TPD52L2), a member of the TPD52 family implicated in cellular processes such as vesicle trafficking, cell proliferation, and apoptosis. The TPD52 family comprises four paralogs (TPD52. TPD52L1. TPD52L2. TPD52L3) that share conserved coiled-coil domains but exhibit tissue-specific expression patterns. TPD52L2. located on chromosome 20q13.33. encodes a small, calcium-binding protein involved in membrane dynamics and protein interactions, particularly in secretory pathways. Dysregulation of TPD52L2 has been linked to cancers, including prostate, breast, and colorectal malignancies, where its overexpression correlates with tumor progression and poor prognosis. It is also associated with immune regulation and neurodegenerative conditions.
TPD52L2 antibodies are essential tools for studying the protein's expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to assess TPD52L2 levels in normal versus diseased tissues. Commercially available antibodies are typically raised against specific epitopes, such as recombinant protein fragments or synthetic peptides, and validated for specificity through knockdown/knockout controls. Researchers utilize these antibodies to explore TPD52L2's role in cancer signaling pathways, its interaction with binding partners (e.g., annexins, SNARE proteins), and potential therapeutic targeting. Reliable TPD52L2 antibodies are critical for advancing studies in oncology, cell biology, and biomarker discovery.